{
    "clinical_study": {
        "@rank": "4950", 
        "brief_summary": {
            "textblock": "This is a post-marketing surveillance study on a marketed cetrizine hydrochloride\n      formulation."
        }, 
        "brief_title": "Contac Bien Z Adverse Effect Survey", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Allergic Rhinitis", 
            "Seasonal Allergic Rhinitis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Rhinitis, Allergic, Seasonal", 
                "Rhinitis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female participants, between 15-65 years of age, who purchase the marketed\n             cetrizine hydrochloride formulation\n\n        Exclusion Criteria:\n\n          -  Who have ever experienced allergic symptoms by taking this medication or any\n             component of this medication, piperazine derivative (including levocetirizine,\n             hydroxizine)\n\n          -  Those who have been under 15en diagnosed with kidney disease\n\n          -  Children under 15 years of age"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "15 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Participants who purchase the marketed cetrizine hydrochloride formulation from pharmacy\n        stores in Japan."
            }
        }, 
        "enrollment": {
            "#text": "1500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02020902", 
            "org_study_id": "RH01905"
        }, 
        "intervention": {
            "description": "As provided on the patient information leaflet", 
            "intervention_name": "Cetrizine hydrochloride", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 19, 2013", 
        "location": {
            "contact": {
                "email": "info@GSKClinicalSupportHD@gsk.com", 
                "last_name": "US GSK Clinical Trials Call Center", 
                "phone": "877-379-3718"
            }, 
            "contact_backup": {
                "email": "info@GSKClinicalSupportHD@gsk.com", 
                "last_name": "EU GSK Clinical Trials Call Center", 
                "phone": "+44 (0) 20 8990 4466"
            }, 
            "facility": {
                "address": {
                    "city": "Saitama", 
                    "country": "Japan", 
                    "zip": "340-0144"
                }, 
                "name": "Drug Store Seki"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_groups": "1", 
        "official_title": "Contac Bien Z Adverse Effect Survey", 
        "overall_contact": {
            "email": "GSKClinicalSupportHD@gsk.com", 
            "last_name": "US GSK Clinical Trials Call Center", 
            "phone": "877-379-3718"
        }, 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Pharmaceutical and Medical Devices Agency: Japan", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Participants will answer a questionnaire which consists of questions on safety of the marketed cetrizine hydrochloride formulation.", 
            "measure": "Adverse events after having cetrizine hydrochloride", 
            "safety_issue": "Yes", 
            "time_frame": "At baseline"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02020902"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Participants will answer a questionnaire which consists of questions on their satisfaction after taking the marketed cetrizine hydrochloride formulation. The efficacy will be measured on a 4 point scale (1 Efficacious; 2 Somewhat efficacious; 3 Not efficacious; 4 Not known", 
            "measure": "Efficacy of the marketed cetrizine hydrochloride formulation", 
            "safety_issue": "No", 
            "time_frame": "At baseline"
        }, 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "December 2013"
    }
}